In a press release dated May 7th, Elanco Animal Health [ELAN] reported on the first quarter of Fiscal 2020 ending March 31st.

For the period, the company posted a net loss of $49.1 million on revenue of $657.7 million, with an EPS of [$0.12].  Corresponding figures for the first quarter of Fiscal 2019 were a net profit of $31.5 million on revenue of $731.1 million with an EPS of $0.09.

For the quarter, Companion Animal products represented 31 percent of revenue and Food Animals, 66 percent.

Companion Animal revenue decreased by 24 percent after the effect of foreign exchange.  Food Animal revenue fell by eight percent due the loss of sales of Paylean® for hogs and Rumensin® for ruminants.

ELAN has a market capitalization of $8.27 billion.  The company traded over a 52-week range of $15.17 to $35.46, with a 50-day moving average of $22.26.

On May 7th after the Q1 release, ELAN fell 10 percent to $20.71.  Elanco posted a 12-month trailing return on assets of 2.6 percent and 1.3 percent on equity.  Operating margin attained 12.1 percent and profit margin 2.2 percent.

The company did not provide forward guidance based on uncertainties relating to COVID-19.